Browse > Article

Antagonic Effects of Dexamethasone on FK506-induced Antitumor Effects in Hep3B Cells  

Park, Hye-Min (College of Veterinary Medicine, Chonbuk National University)
Lee, Sei-Jin (Korea Basic Science Institute Jeonju Center)
Kim, Sun-Young (College of Veterinary Medicine, Chonbuk National University)
Go, Hyeon-Kyu (College of Veterinary Medicine, Chonbuk National University)
Jeon, Seol-Hee (College of Veterinary Medicine, Chonbuk National University)
Kim, Shang-Jin (Korean Zoonoses Research Institute, Chonbuk National University)
Kang, Hyung-Sub (Korean Zoonoses Research Institute, Chonbuk National University)
Kim, Jin-Shang (Korean Zoonoses Research Institute, Chonbuk National University)
Publication Information
Journal of Veterinary Clinics / v.28, no.6, 2011 , pp. 549-554 More about this Journal
Abstract
FK506 is a widespread immunosuppressive drug after liver transplantion in patients with advanced-stage hepatocellular carcinoma. Dexamethasone is frequently used as co-treatment in cytotoxic cancer therapy, e.g. to prevent nausea, to protect normal tissue or for other reasons. Our aim was to investigate antitumor effects of FK506 in Hep3B cells, one of differentiated human hepatocellular carcinoma cell lines and inhibitory effects of dexamethsone on FK506- induced antitumor effects. Cell injury was evaluated by biochemical assays as cell viability, lactate dehydrogenase (LDH) and reactive oxygen species (ROS) in Hep3B cells. Intracellular calcium concentration ([$Ca^{2+}$]i) and the level of activation of the c-Jun-N-terminal kinase (JNK) and the Bax protein in cultured Hep3B cells was measured. Exposure of 0.1 ${\mu}M$ FK506 to Hep3B cells led to cell death accompanied by a decrease in cell viability and an increase in LDH, ROS and [$Ca^{2+}$]i. FK506 induced an increase in activity of Bax and JNK protein but inhibited the activity of Bcl-2 protein. Treatment of dexamethsone, per se, had no effects on cell viability, LDH and ROS. However, co-treatment of FK506 and dexamethasone diminished the FK506-induced LDH release, ROS generation and JNK activation. These results demonstrate that FK506 has antitumor effect in Hep3B cells but the combination of FK506 and dexamethasone antagonizes the FK506-induced antitumor effects.
Keywords
hepatocellular carcinoma cell line (Hep3B); FK506; dexamethasone;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Mazzaferro V, Rondinara GF, Rossi G, Regalia E, De Carlis L, Caccamo L, Doci R, Sansalone CV, Belli LS, Armiraglio E. Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplant Proc 1994; 26: 3557-3560.
2 Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001; 7: 473-484.   DOI   ScienceOn
3 Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Int J Cancer 2001; 94: 153-156.   DOI   ScienceOn
4 Petrella A, Ercolino SF, Festa M, Gentilella A, Tosco A, Conzen SD, Parente L: Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer 2006; 42: 3287-3293.   DOI   ScienceOn
5 Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360: 1969-1970.   DOI   ScienceOn
6 Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 2004; 3: 715-718.   DOI   ScienceOn
7 Sakai M, Miyake H, Tashiro S, Okumura Y, Kido H. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells. Med Invest 2003; 51: 63-69.
8 Yazawa H, Kato T, Nakada T, Sendo F. Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell. cytostasis. Int J Cancer 1999; 81: 74-80.   DOI   ScienceOn
9 Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991; 68: 2095-2100.   DOI   ScienceOn
10 Zhang C, Kolb A, Mattern J, Gassler N, Wenger T, Herzer K, Debatin KM, Bu hler M, Friess H, Rittgen W, Edler L, Herr I. Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Letters 2006; 242: 104-111.   DOI   ScienceOn
11 Lipton SA, Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 1998; 23: 165-171.   DOI
12 Buttke TM, Sandstrom PM. Oxidative stress as a mediator of apoptosis. Immunol Today 1994; 15: 7-10.   DOI   ScienceOn
13 Chen ZS, Zeng FJ, Ming CS, Lin ZB, Zhang WJ, Wei L, Zhu XH, Jiang JP, Chen ZK. The survival and value of liver transplantation for liver carcinoma: a single-center experience. Transplant Proc 2004; 36: 2284-2286.   DOI   ScienceOn
14 Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.   DOI   ScienceOn
15 Grabarevic Z, Coric M, Seiwerth S, Dzaja P, Artukovic B, Kurilj AG, Beck A, Hohsteter M, Sostari -Zuckermann IC, Brcic L, Hrstic I. Comparative analysis of hepatocellular carcinoma in men and dogs. Coll Antropol 2009; 33:811-814.
16 Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 2004; 95: 644-650.   DOI   ScienceOn
17 Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol 2005; 11: 6373-6380.   DOI